

**Vector pCAGGS Containing the SARS-Related Coronavirus 2, Wuhan-Hu-1 Spike Glycoprotein Gene Receptor Binding Domain (RBD)**

**Catalog No. NR-52309**

This reagent is the tangible property of the U.S. Government.

**Product Description:**

The vector for the receptor binding domain (RBD) of the spike (S) glycoprotein gene from severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2), Wuhan-Hu-1 (GenBank: [MN908947](#)) was designed by fusing the N-terminal S protein signal sequence to the spike RBD (amino acids 319 to 541) with a C-terminal hexa-histidine tag. The sequence was codon optimized for mammalian expression and subcloned into the [pCAGGS](#) mammalian expression vector. NR-52309 contains the beta-lactamase gene, *bla*, to provide transformant selection through ampicillin resistance in *Escherichia coli* (*E. coli*). Lot 70034636 was produced from a preparation of glycerol stock (NRC-52309 lot 70033696), grown in Luria-Bertani broth with ampicillin (50 µg per mL) for 1 day at 37°C in an aerobic atmosphere, extracted using a Plasmid *Plus* Maxi Kit (QIAGEN® 12963) and vialled in TE buffer (10 mM Tris-HCl, 1 mM EDTA, pH 8.0).

**Lot: 70034636**


**Manufacturing Date: 03APR2020**

TEST	SPECIFICATIONS	RESULTS
<b>Next-Generation DNA Sequencing<sup>1</sup></b>	~ 5490 base pairs	5498 base pairs
<b>Genotypic Analysis<sup>1</sup></b> Sequencing of spike RBD insert (~ 740 base pairs)	≥ 99% sequence identity to depositor's sequence C-terminal hexa-histidine tag confirmed	100% sequence identity to depositor's sequence C-terminal hexa-histidine tag confirmed
<b>Antibiotic Resistance<sup>1</sup></b> Ampicillin (encoded by beta-lactamase gene <i>bla</i> ) <sup>2</sup>	<i>bla</i> sequence present	<i>bla</i> sequence present
<b>Agarose Gel Electrophoresis</b> Digestion with <i>SapI</i> and <i>SacI</i>	~ 1 kb and ~ 4 kb	~ 1 kb and ~ 4 kb (Figure 1)
<b>Concentration by Qubit™ Measurement</b>	Report results	1.4 µg in 100 µL per vial (14 µg/mL)
<b>Amount per Vial</b>	Report results	1.4 µg per vial
<b>OD<sub>260</sub>/OD<sub>280</sub> Ratio (pre-vial)</b>	1.7 to 2.1	2.0
<b>Effective Bacterial Transformation</b> Invitrogen™ One Shot™ TOP10 <i>E. coli</i>	≥ 50 colonies per ng	Not determined

<sup>1</sup>This test was performed pre-vial on a previous lot of extracted material (NR-52309 lot 70033695).

<sup>2</sup>The antibiotic ampicillin degrades quickly during growth. Bacterial stationary phase should be minimized during plasmid expansion to avoid plasmid loss and increased antibiotic concentrations may be necessary.

Figure 1: Agarose Gel of Undigested and Restriction Enzyme Digested NR-52309



Lane 1: Invitrogen™ TrackIt™ 1 Kb Plus DNA Ladder  
Lane 2: NR-52309 undigested  
Lane 3: NR-52309 digested

/Heather Couch/  
Heather Couch

Program Manager or designee, ATCC Federal Solutions

10 APR 2020

ATCC®, on behalf of BEI Resources, hereby represents and warrants that the material provided under this certificate has been subjected to the tests and procedures specified and that the results described, along with any other data provided in this certificate, are true and accurate to the best of ATCC®'s knowledge.

ATCC® is a trademark of the American Type Culture Collection.  
You are authorized to use this product for research use only. It is not intended for human use.

